VKTX
Viking Therapeutics, Inc.
Nasdaq: VKTX · San Diego, CA · Healthcare
$24.40-1.43 (-5.54%)Closed
Market Cap$2.85B
Cash$125.8Mmost recent
Runway3 mo$114.0M Q burn
P/E (TTM)—EPS $-3.19
52-Wk Range$24.40 – $42.13
Avg Volume3.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$24.40-66.7%
Pipeline
Drug candidates sponsored by Viking Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | VK2735 | Weight Loss+1 more | Active, not recruiting | 2027-07-01 | 5 | |
| Phase 3 | VK2735 Oral | Weight Loss | Not yet recruiting | 2028-10 | 1 | |
| Phase 2 | VK5211 | Hip Fractures | Completed | 2017-11-15past | 1 | |
| Phase 2 | VK2809 | Hyperlipidemia+2 more | Completed | 2023-05-15past | 2 | |
| Phase 2 | Placebo | Weight Loss | Completed | 2025-06-24past | 1 | |
| Phase 1 | VK0214 | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | Completed | 2024-10-09past | 1 | |
| Phase 1 | SC VK3019 | Obese Adults | Recruiting | 2026-10-02past | 1 | |
| Phase 1 | VK2735 Drug | Obese Adults | Recruiting | 2027-05 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for VKTX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.